Revolution Medicines, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
214.2M
on 2026-06-30, from 164.9M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
S-3ASR of 2024-05-08. Not read yet. S-3ASR ↗
$1.00B
TD Securities (USA), agreement of 2024-08-07. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-05 is not read yet.
Cash
12.9 quarters
$3.94B on 2026-06-30 ÷ $305.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-04-15 | Public offering | 10,563,381 | $142.00 | $1.50B | 424B5 ↗ |
Also on file: up to $250.0M revenue notes agreed 2025-06-24 8-K ↗ · $500.0M convertible notes, 2026-04-14 424B5 ↗ · $1K convertible notes, 2026-04-17 8-K ↗